Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02130557




Registration number
NCT02130557
Ethics application status
Date submitted
1/05/2014
Date registered
5/05/2014
Date last updated
18/05/2021

Titles & IDs
Public title
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Scientific title
A MULTICENTER PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Secondary ID [1] 0 0
2013-005101-31
Secondary ID [2] 0 0
AV001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Bosutinib
Treatment: Drugs - Imatinib

Experimental: Bosutinib - Bosutinib, 400 mg, oral administration once a day

Active comparator: Imatinib - Imatinib, 400 mg, oral administration once a day


Treatment: Drugs: Bosutinib
Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.

Treatment: Drugs: Imatinib
Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.

Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Major Molecular Response (MMR) at Month 12
Timepoint [1] 0 0
Month 12
Secondary outcome [1] 0 0
Percentage of Participants With Major Molecular Response (MMR) Up to Month 18
Timepoint [1] 0 0
Up to Month 18
Secondary outcome [2] 0 0
Kaplan-Meier Estimate of Probability of Retaining Major Molecular Response (MMR) at Month 48
Timepoint [2] 0 0
Month 48
Secondary outcome [3] 0 0
Percentage of Participants With Complete Cytogenetic Response (CCyR) Up to Month 12
Timepoint [3] 0 0
Up to Month 12
Secondary outcome [4] 0 0
Kaplan-Meier Estimate of Probability of Retaining Complete Cytogenetic Response (CCyR) at Month 48
Timepoint [4] 0 0
Month 48
Secondary outcome [5] 0 0
Cumulative Incidence of Event Free Survival (EFS) Events
Timepoint [5] 0 0
Up to Month 60
Secondary outcome [6] 0 0
Overall Survival (OS) Rate
Timepoint [6] 0 0
Up to Month 60

Eligibility
Key inclusion criteria
1. Molecular diagnosis of CP CML of = 6 months (from initial diagnosis).
2. Adequate hepatic, renal and pancreatic function.
3. Age = 18 years.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with the exception of hydroxyurea and/or anagrelide treatment, which are permitted for up to 6 months prior to study entry (signature of ICF) if suitably approved for use in the subject's region.
2. Any past or current Central Nervous System (CNS) involvement, including leptomeningeal leukemia.
3. Extramedullary disease only.
4. Major surgery or radiotherapy within 14 days of randomization.
5. History of clinically significant or uncontrolled cardiac disease.
6. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, cirrhosis or evidence of decompensated liver disease. Patients with resolved Hepatitis B can be included.
7. Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease, Ulcerative Colitis, or prior total or partial gastrectomy.
8. History of another malignancy within 5 years with the exception of basal cell carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least l2 months.
9. Current, or recent (within 30 days, or 5 half-lives of investigational product) participation in other clinical trials of investigational agents and/or containing interventional procedures deemed contrary to the objectives and conduct of this trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/07/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/04/2020
Sample size
Target
Accrual to date
Final
536
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
St George Hospital - Hematology Department - Kogarah
Recruitment hospital [2] 0 0
Eastern Clinical Research Unit, Level 2 - Box Hill
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Hawaii
Country [4] 0 0
United States of America
State/province [4] 0 0
Idaho
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Mississippi
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New Mexico
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Belgium
State/province [24] 0 0
Ghent
Country [25] 0 0
Belgium
State/province [25] 0 0
Leuven
Country [26] 0 0
Belgium
State/province [26] 0 0
Liège
Country [27] 0 0
Belgium
State/province [27] 0 0
Verviers
Country [28] 0 0
Canada
State/province [28] 0 0
New Brunswick
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
Canada
State/province [31] 0 0
Saskatchewan
Country [32] 0 0
Czechia
State/province [32] 0 0
Brno
Country [33] 0 0
Czechia
State/province [33] 0 0
Hradec Králové
Country [34] 0 0
Czechia
State/province [34] 0 0
Olomouc
Country [35] 0 0
Czechia
State/province [35] 0 0
Prague
Country [36] 0 0
Denmark
State/province [36] 0 0
Aalborg
Country [37] 0 0
Denmark
State/province [37] 0 0
Aarhus
Country [38] 0 0
Denmark
State/province [38] 0 0
Roskilde
Country [39] 0 0
Finland
State/province [39] 0 0
Helsinki
Country [40] 0 0
France
State/province [40] 0 0
NC
Country [41] 0 0
France
State/province [41] 0 0
Bordeaux
Country [42] 0 0
France
State/province [42] 0 0
Le Chesnay
Country [43] 0 0
France
State/province [43] 0 0
Nantes cedex 1
Country [44] 0 0
France
State/province [44] 0 0
Nice
Country [45] 0 0
France
State/province [45] 0 0
Nimes
Country [46] 0 0
France
State/province [46] 0 0
Pierre Bénite
Country [47] 0 0
France
State/province [47] 0 0
Poitiers
Country [48] 0 0
France
State/province [48] 0 0
Toulouse cedex 9
Country [49] 0 0
Germany
State/province [49] 0 0
RP
Country [50] 0 0
Germany
State/province [50] 0 0
Aachen
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Freiburg
Country [53] 0 0
Germany
State/province [53] 0 0
Hamburg
Country [54] 0 0
Germany
State/province [54] 0 0
Jena Lobeda-Ost
Country [55] 0 0
Germany
State/province [55] 0 0
Magdeburg
Country [56] 0 0
Hungary
State/province [56] 0 0
Budapest
Country [57] 0 0
Hungary
State/province [57] 0 0
Debrecen
Country [58] 0 0
Hungary
State/province [58] 0 0
Györ
Country [59] 0 0
Hungary
State/province [59] 0 0
Kaposvár
Country [60] 0 0
Hungary
State/province [60] 0 0
Szeged
Country [61] 0 0
Hungary
State/province [61] 0 0
Szolnok
Country [62] 0 0
Israel
State/province [62] 0 0
Haifa
Country [63] 0 0
Israel
State/province [63] 0 0
Petah-Tikva
Country [64] 0 0
Italy
State/province [64] 0 0
CT
Country [65] 0 0
Italy
State/province [65] 0 0
Bergamo
Country [66] 0 0
Italy
State/province [66] 0 0
Bologna
Country [67] 0 0
Italy
State/province [67] 0 0
Cagliari
Country [68] 0 0
Italy
State/province [68] 0 0
Firenze
Country [69] 0 0
Italy
State/province [69] 0 0
Genova
Country [70] 0 0
Italy
State/province [70] 0 0
Milano
Country [71] 0 0
Italy
State/province [71] 0 0
Monza
Country [72] 0 0
Italy
State/province [72] 0 0
Napoli
Country [73] 0 0
Italy
State/province [73] 0 0
Reggio Calabria
Country [74] 0 0
Italy
State/province [74] 0 0
Roma
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Anyang-si
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Busan
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Daegu
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Jeonju
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Seoul
Country [80] 0 0
Mexico
State/province [80] 0 0
DF
Country [81] 0 0
Mexico
State/province [81] 0 0
Nuevo LEON
Country [82] 0 0
Netherlands
State/province [82] 0 0
Noord Holland
Country [83] 0 0
Netherlands
State/province [83] 0 0
Noord-holland
Country [84] 0 0
Norway
State/province [84] 0 0
Bergen
Country [85] 0 0
Norway
State/province [85] 0 0
Trondheim
Country [86] 0 0
Poland
State/province [86] 0 0
Pomorskie
Country [87] 0 0
Poland
State/province [87] 0 0
Chorzow
Country [88] 0 0
Poland
State/province [88] 0 0
Katowice
Country [89] 0 0
Poland
State/province [89] 0 0
Kraków
Country [90] 0 0
Poland
State/province [90] 0 0
Lublin
Country [91] 0 0
Poland
State/province [91] 0 0
Wroclaw
Country [92] 0 0
Poland
State/province [92] 0 0
Lódz
Country [93] 0 0
Singapore
State/province [93] 0 0
Singapore
Country [94] 0 0
Slovakia
State/province [94] 0 0
Bratislava
Country [95] 0 0
South Africa
State/province [95] 0 0
Gauteng
Country [96] 0 0
South Africa
State/province [96] 0 0
Western CAPE
Country [97] 0 0
Spain
State/province [97] 0 0
Barcelona
Country [98] 0 0
Spain
State/province [98] 0 0
Málaga
Country [99] 0 0
Spain
State/province [99] 0 0
Madrid
Country [100] 0 0
Spain
State/province [100] 0 0
Salamanca
Country [101] 0 0
Spain
State/province [101] 0 0
Toledo
Country [102] 0 0
Spain
State/province [102] 0 0
Valencia
Country [103] 0 0
Sweden
State/province [103] 0 0
Linköping
Country [104] 0 0
Sweden
State/province [104] 0 0
Lund
Country [105] 0 0
Sweden
State/province [105] 0 0
Stockholm
Country [106] 0 0
Sweden
State/province [106] 0 0
Umeå
Country [107] 0 0
Sweden
State/province [107] 0 0
Uppsala
Country [108] 0 0
Taiwan
State/province [108] 0 0
R.o.c.
Country [109] 0 0
Taiwan
State/province [109] 0 0
Kaohsiung City
Country [110] 0 0
Thailand
State/province [110] 0 0
Chiang MAI
Country [111] 0 0
Thailand
State/province [111] 0 0
Bangkok
Country [112] 0 0
Ukraine
State/province [112] 0 0
Cherkasy
Country [113] 0 0
Ukraine
State/province [113] 0 0
Ivano-Frankivsk
Country [114] 0 0
Ukraine
State/province [114] 0 0
Khmelnytskyi
Country [115] 0 0
Ukraine
State/province [115] 0 0
Kyiv
Country [116] 0 0
Ukraine
State/province [116] 0 0
Lviv
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Greater London
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Merseyside
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Nottinghamshire
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Oxfordshire
Country [121] 0 0
United Kingdom
State/province [121] 0 0
South Yorkshire
Country [122] 0 0
United Kingdom
State/province [122] 0 0
WEST Midlands
Country [123] 0 0
United Kingdom
State/province [123] 0 0
WEST Yorkshire
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Cardiff
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Leicester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
Trial website
https://clinicaltrials.gov/study/NCT02130557
Trial related presentations / publications
Brummendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, Rousselot P, Mauro MJ, Hochhaus A, Hurtado Monroy R, Leip E, Purcell S, Yver A, Viqueira A, Deininger MW; BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 Jul;36(7):1825-1833. doi: 10.1038/s41375-022-01589-y. Epub 2022 May 28.
Takahashi N, Cortes JE, Sakaida E, Ishizawa K, Ono T, Doki N, Matsumura I, Garcia-Gutierrez V, Rosti G, Ono C, Ohkura M, Tanetsugu Y, Viqueira A, Brummendorf TH. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. Int J Hematol. 2022 Jun;115(6):838-851. doi: 10.1007/s12185-022-03314-y. Epub 2022 Mar 2.
Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, Ohkura M, Ono C, Viqueira A, Cortes JE, Brummendorf TH. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021 Jul;114(1):65-78. doi: 10.1007/s12185-021-03144-4. Epub 2021 Apr 13.
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brummendorf TH. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02130557